$102.85
1.46% today
NYSE, Dec 05, 05:15 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$101.37
-0.50 0.49% 1M
-27.34 21.24% 6M
-7.65 7.02% YTD
-3.69 3.51% 1Y
+27.95 38.07% 3Y
+16.82 19.89% 5Y
+43.28 74.51% 10Y
NYSE, Closing price Wed, Dec 04 2024
-0.48 0.47%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Market capitalization $256.43b
Enterprise Value $279.98b
P/E (TTM) P/E ratio 21.23
EV/FCF (TTM) EV/FCF 18.87
EV/Sales (TTM) EV/Sales 4.45
P/S ratio (TTM) P/S ratio 4.08
P/B ratio (TTM) P/B ratio 5.77
Dividend yield 3.08%
Last dividend (FY24) $3.12
Revenue growth (TTM) Revenue growth 8.17%
Revenue (TTM) Revenue $62.89b
EBIT (operating result TTM) EBIT $14.47b
Free Cash Flow (TTM) Free Cash Flow $14.84b
Cash position $14.64b
EPS (TTM) EPS $4.77
P/E forward 13.75
P/S forward 4.01
EV/Sales forward 4.38
Short interest 1.04%
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

21x Buy
78%
6x Hold
22%

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

Buy
78%
Hold
22%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62,893 62,893
8% 8%
100%
- Direct Costs 16,965 16,965
2% 2%
27%
45,928 45,928
12% 12%
73%
- Selling and Administrative Expenses 6,463 6,463
0% 0%
10%
- Research and Development Expense 20,800 20,800
8% 8%
33%
18,665 18,665
58% 58%
30%
- Depreciation and Amortization 4,198 4,198
10% 10%
7%
EBIT (Operating Income) EBIT 14,467 14,467
80% 80%
23%
Net Profit 12,148 12,148
164% 164%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Neutral
Seeking Alpha
about one hour ago
Merck & Co. Inc. (NYSE:MRK ) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Development and CMO Conference Call Participants Geoff Meacham - Citi Geoff Meacham Welcome to the morning session of the First Annual Citi Global Healthcare Conference. My name is Geoff Meacham.
Neutral
Business Wire
about 4 hours ago
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #AfricaAsiaLuminary--Merck Foundation, conducted the 11th Edition of their annual conference, “Merck Foundation Africa Asia Luminary”.
Neutral
Business Wire
about 5 hours ago
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 72,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today